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Abstract
HIV infection usually leads to a progressive decline in number and functionality of CD4+ T lymphocytes, resulting in AIDS
development. In this study, I investigated the strategy of using inoculated SupT1 cells to move infection from HIV-1 X4
strains toward the inoculated cells, which should theoretically prevent infection and depletion of normal CD4+ T cells,
preventing the development of AIDS-related pathologies. Interestingly, the persistent in vitro replication in SupT1 cells
renders the virus less cytopathic and more sensitive to antibody-mediated neutralization, suggesting that replication of
the virus in the inoculated SupT1 cells may have a vaccination effect in the long run. In order to mimic the scenario of a
therapy in which SupT1 cells are inoculated in an HIV-seropositive patient, I used infected SupT1/PBMC cocultures and a
series of control experiments. Infections were done with equal amounts of the wild type HIV-1 LAI virus. The SupT1
CD4+CD8+ T cell population was distinguished from the PBMC CD4+CD82 T cell population by FACS analysis. The results
of this study show that the virus-mediated killing of primary CD4+ T cells in the SupT1/PBMC cocultures was significantly
delayed, suggesting that the preferential infection of SupT1 cells can induce the virus to spare primary CD4+ T cells from
infection and depletion. The preferential infection of SupT1 cells can be explained by the higher viral tropism for the
SupT1 cell line. In conclusion, this study demonstrates that it’s possible in an in vitro system to use SupT1 cells to prevent
HIV infection of primary CD4+ T cells, suggesting that further exploration of the SupT1 cell line as a cell-based therapy
against HIV-1 may prove worthwhile.
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Introduction
It was reported by a previous in vitro study that the X4 HIV-1
virus has a higher tropism for SupT1 cells than for primary CD4+
T cells [1]. Several hypotheses have been proposed as an
explanation, most notably the higher surface expression of CD4
and CXCR4 receptors in SupT1 cells. It was also reported by HIV
in vitro evolution studies that the persistent growth of the virus in
the SupT1 cell line results in a less cytopathic virus with reduced
capacity for syncytium formation, higher sensitivity to antibody-
mediated neutralization, improved replication in SupT1 cells and
impaired infection of primary CD4+ T cells [1–4]. The leukemic
SupT1 cells are probably less susceptible to apoptosis than primary
CD4+ T cells, allowing the lengthening of the period of virus
production before the infected cell dies. This can improve viral
replication efficiency and may also induce the virus to lose the
costly escape mutations that hamper its replication ability;
therefore, the selection of less virulent HIV-1 variants is the
evolutionary route chosen by the virus. As reported by previous
studies, it was observed increased viral production of HIV-infected
CD4+T cells treated with caspase inhibitors that prevent cell death
[5,6], supporting the idea that viral replication efficiency improves
in cells that are less susceptible to apoptosis. Another consideration
regarding viral replication and viral evolution is related to the Vif
protein. The HIV-1 accessory protein Vif is essential for
replication in ‘‘nonpermissive’’ primary CD4+ T cells, in order
to prevent hypermutation of newly-made HIV-DNA by cellular
cytidine deaminase [7,8]. Some ‘‘permissive’’ T cell lines (e.g.,
Jurkat and SupT1) lack deaminase activity [9] and fully support
HIV-1 spread in the absence of Vif [10,11], making Vif a
nonessential viral protein for replication in SupT1 cells. The
absence of cellular host restriction factors like cytidine deaminase
may also explain the enhanced replication of the HIV-1 virus in
the SupT1 cell line. Furthermore, the Vif protein shows that an
essential protein for replication in primary CD4+ T cells might be
a nonessential protein for replication in SupT1 cells. This supports
the idea that many unnecessary genes could be deleted during the
course of adaptation to growth in SupT1 cells, resulting in the
development of less virulent HIV-1 variants. Considering the cited
literature data, the SupT1 seems to be an interesting cell line to
investigate as a possible cell-based therapy against HIV-1. HIV
infection usually leads to a progressive decline in number and
functionality of CD4+ T lymphocytes, resulting in AIDS
development [12]. In this study, I investigated the strategy of
using inoculated SupT1 cells to move infection from HIV-1 X4
strains toward the inoculated cells, which should theoretically
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nprevent infection and depletion of normal CD4+ T cells,
preventing the development of AIDS-related pathologies.
Interestingly, the cited HIV in vitro evolution studies reported
that the persistent in vitro replication in SupT1 cells renders the
virus less cytopathic and more sensitive to antibody-mediated
neutralization, suggesting that replication of the virus in the
inoculated SupT1 cells may have a vaccination effect in the long
run. In the real scenario of a therapy in which SupT1 cells are
inoculated in an HIV-seropositive patient, the blood of the patient
will contain a combination of SupT1 and normal CD4+T cells. In
this situation the HIV-1 virus should preferentially infect SupT1
cells. In addition, the virus should completely eradicate SupT1
cells from the blood of the patient, preventing the uncontrolled
replication of SupT1 cells. In order to mimic this scenario in my in
vitro experiment, I used infected SupT1/PBMC cocultures and a
series of control experiments. Infections were done with equal
amounts of the wild type HIV-1 LAI virus. The SupT1
CD4+CD8+ T cell population was distinguished from the PBMC
CD4+CD82 T cell population by FACS analysis. The wild type
HIV-1 LAI virus replicated efficiently in all cultures; however, the
virus-mediated killing of primary CD4+ T cells in the SupT1/
PBMC cocultures was significantly delayed. This suggests that the
preferential infection of SupT1 cells can induce the virus to spare
primary CD4+ T cells from infection and depletion. The
preferential infection of SupT1 cells can be explained by the
higher viral tropism for the SupT1 cell line. Eradication of SupT1
cells was obtained on average 9–10 days after infection, and no
evident allogeneic response against SupT1 cells was observed in
the cocultures.
Results
In agreement with the higher viral tropism for the ‘‘permissive’’
SupT1 cell line, in the SupT1/PBMC cocultures the HIV-1 virus
preferentially infects and kills the leukemic SupT1 cell population.
Therefore, 6 days after infection a large part of SupT1 cells were
actively killed by the HIV-1 virus, while only a small fraction of
primary CD4+ T cells were killed (Fig. 1).
By comparison, 6 days after infection all PBMC cultures showed
complete eradication of primary CD4+ T cells (Fig. 2). These
results suggest that the preferential infection of SupT1 cells can
induce the virus to delay infection and depletion of primary cells.
Examination of primary CD4+ T cell proliferation in the
presence of SupT1 cells
In order to avoid misinterpretation of the data regarding
primary CD4+ T cell survival, the proliferation of primary cells in
the presence of SupT1 cells was examined in this study. Allogeneic
Figure 1. Infected SupT1/PBMC coculture and uninfected control. Infection was done with a virus input of 60 ng CA-p24 wild type HIV-1 LAI
virus. In order to distinguish natural cell death from virus-mediated cell death (especially important for primary CD4+ T cells due to lower vitality and
proliferation than SupT1 cells), the virus-mediated cell killing was determined by comparing the number of live cells in the infected coculture with the
number of live cells in the uninfected control coculture. The results shown are from a representative experiment. The experiment was repeated ten
times, and similar results were obtained (see Fig. 4 and Fig. 5 for details).
doi:10.1371/journal.pone.0037511.g001
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inducing activation and clonal expansions of primary CD4+ T
cells. Therefore, the perceived survival of primary CD4+ T cells in
the infected SupT1/PBMC cocultures could simply be a transient
alloexpansion that eventually dies out. In such a case, the
uninfected SupT1/PBMC cocultures would show higher prolifer-
ation of primary CD4+ T cells in comparison with the uninfected
PBMC cultures. However, the growth curves of primary cells in
these control experiments are similar (Fig. 1, Fig. 2), showing no
evident sign of a strong alloexpansion. Another observation is that
if the alloexpansion were present, it would be present in both
infected and uninfected cocultures. Therefore, by comparing the
number of live primary CD4+ T cells in the infected cocultures
with the number of live primary CD4+ T cells in the
corresponding uninfected control cocultures, even if there were
the alloexpansion, the virus-mediated cell killing would still be
shown. Considering this, if the preferential infection of SupT1 cells
didn’t prevent infection of primary CD4+ T cells, the killing of
primary cells would be shown. However, in the first 5 days of
infection no evident killing of primary CD4+ T cells is shown by
comparing the infected SupT1/PBMC cocultures with the
uninfected SupT1/PBMC cocultures (Fig. 1).
The killing of primary CD4+ T cells in the infected SupT1/
PBMC cocultures started to be strong on average 7–8 days post
infection, when the large majority of SupT1 cells were removed by
the HIV-1 virus (Fig. 1). Thus, the presence of SupT1 cells seems
to be directly responsible for the delayed virus-mediated killing of
primary CD4+ T cells. In addition, no evident killing of SupT1
cells by allogeneic cytotoxic response is shown by comparing the
number of live SupT1 cells in the uninfected SupT1/PBMC
cocultures with the number of live SupT1 cells in the uninfected
SupT1 cultures (Fig. 1, Fig. 3). This suggests that the HIV-1 virus
was entirely responsible for killing and eradicating SupT1 cells in
the infected cocultures. The results of all the experiments are
summarized with means and standard deviations in Fig. 4 and
Fig. 5, detailed examination of the difference in primary CD4+ T
cell survival between the infected SupT1/PBMC cocultures and
the infected PBMC cultures (with statistical significance) is
provided in Fig. 6.
Discussion
In this study, the killing of primary CD4+ T cells in the infected
cocultures started to be vigorous when the large majority of SupT1
cells were removed by the HIV-1 virus. This suggests that in the
real scenario of a cell-based therapy, after the complete
eradication of the inoculated SupT1 cells by the HIV-1 virus,
every potential therapeutic effect will end. Therefore, in order to
maintain the supposed therapeutic effects, the inoculation with
SupT1 cells will need to be repeated over time. Several serious
Figure 2. Infected PBMC culture and uninfected control. Infection was done with a virus input of 60 ng CA-p24 wild type HIV-1 LAI virus. In
order to distinguish natural cell death from virus-mediated cell death, the virus-mediated cell killing was determined by comparing the number of
live cells in the infected culture with the number of live cells in the uninfected control culture. The results shown are from a representative
experiment. The experiment was repeated ten times, and similar results were obtained (see Fig. 4 and Fig. 5 for details).
doi:10.1371/journal.pone.0037511.g002
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inoculations with SupT1 cells as a therapy against the virally
induced CD4+ T cell depletion. A first safety issue could be related
to the risk of developing T-cell acute lymphocytic leukemia.
However, as previously mentioned, the virus should completely
eradicate SupT1 cells from the blood of the patient, preventing the
uncontrolled replication of SupT1 cells. A second safety concern is
that the cytokines produced by SupT1 cells may affect the immune
system. In this regard, one may think about having IL-2, IL-12 or
IL-15 expression plasmid transfected into SupT1 cells to enhance
HIV-specific Th1 immune response [13], but the risk of
introducing an uncontrolled cytokine loop may hamper this
approach.
Another issue could be related to the development of a strong
allogeneic response against SupT1 cells. Although no killing of
SupT1 cells by allogeneic response was observed in my
experimental setting, it is possible that a patient could develop a
specific immune response against SupT1 cells over time. Strong
killing of SupT1 cells by a specific immune response could limit
the supposed therapeutic effects of the inoculation to a very short
time. However, considering that the blood of a patient with T-cell
leukemia contains a combination of normal and leukemic T cells,
one could argue that if the immune system were able to efficiently
eradicate leukemic T cells, then T-cell leukemia would not be such
an aggressive disease. In this regard, it should be mentioned that
an HIV-1 variant that selectively replicates in leukemic T cells was
proposed as a therapeutic virus against CXCR4-expressing T-
ALL malignancies [14]. Finally, it should also be mentioned that
human inoculation with in vitro grown T cells was already
performed in T cell vaccination [15,16] and Adoptive T cell
therapy [17,18]. Concerning T cell vaccination, the T cell line
cells are weakened with radiation to make them unable to
replicate, these cells are then inoculated in the patient. In order to
make the inoculation with SupT1 cells safer, a similar protocol
could be proposed. In conclusion, this study demonstrates that it’s
possible in an in vitro system to use SupT1 cells to prevent HIV
infection of primary CD4+ T cells, suggesting that further
exploration of the SupT1 cell line as a cell-based therapy against
HIV-1 may prove worthwhile.
Materials and Methods
Cells
The C33A cervical cancer cell line was obtained from the
American Type Culture Collection, ATCC HTB31 [19]. C33A
cells were cultured in Dulbecco’s modified Eagle’s medium
supplemented with 10% FBS, 1% penicillin/streptomycin at
37uC and in 5% CO2.
The SupT1 lymphoblastoid CD4+ T cell line was obtained
from the American Type Culture Collection, ATCC CRL-1942
Figure 3. Infected SupT1 culture and uninfected control. Infection was done with a virus input of 60 ng CA-p24 wild type HIV-1 LAI virus. The
virus-mediated cell killing was determined by comparing the number of live cells in the infected culture with the number of live cells in the
uninfected control culture. The results shown are from a representative experiment. The experiment was repeated ten times, and similar results were
obtained (see Fig. 4 and Fig. 5 for details).
doi:10.1371/journal.pone.0037511.g003
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10% FBS, 1% glutamine, 1% penicillin/streptomycin at 37uC and
in 5% CO2.
Freshly isolated PBMC obtained from buffy coats of healthy
HIV-seronegative donors (Blood Transfusion Center, L. Sacco
Hospital) were cultured in RPMI 1640 supplemented with 10%
FBS, 1% glutamine, 1% penicillin/streptomycin, 100 units/mL IL-
2 and 5 micrograms/mL phytohemagglutinin at 37uC and in 5%
CO2. PBMC from different donors were cultured separately and
never mixed in order to avoid allogeneic response. The protocols
used in this study were approved by the L. Sacco Hospital Ethics
Figure 4. Data regarding repeatability of the experiments. All experiments in this study were repeated ten times; in each experiment,
successive repetitions yielded consistent results. The collected data were summarized using means and standard deviations. This figure shows the
data regarding the infected cultures. In the graphs, the lines show the mean values, and the error bars represent the standard deviations.
doi:10.1371/journal.pone.0037511.g004
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from donors who gave written informed consent.
SupT1/PBMC coculture. 48 h after activation with PHA,
PBMC containing 5 million primary CD4+ T cells were washed
with medium and mixed with 5 million SupT1 cells, and the cell
mixture was cultured in 5 mL of complete medium.
PBMC culture. 48 h after activation with PHA, PBMC
containing 5 million primary CD4+ T cells were resuspended and
cultured in 5 mL of complete medium.
SupT1 culture. 5 million SupT1 cells were resuspended and
cultured in 5 mL of complete medium.
Figure 5. Data regarding repeatability of the experiments. All experiments in this study were repeated ten times; in each experiment,
successive repetitions yielded consistent results. The collected data were summarized using means and standard deviations. This figure shows the
data regarding the uninfected cultures. In the graphs, the lines show the mean values, and the error bars represent the standard deviations.
doi:10.1371/journal.pone.0037511.g005
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Virus stocks were generated by transfection of C33A cells. All
infections were done with a virus input of 60 ng CA-p24 wild type
HIV-1 LAI virus and samples were taken from the cultures for
anti-CD4/CD8 FACS analysis and CA-p24 ELISA analysis.
Flow cytometry
The number of live cells in each culture was determined by
FACS analysis. The PBMC CD4+CD82 T cell population was
distinguished from the SupT1 CD4+CD8+ T cell population by
FACS analysis using DAKO Monoclonal Mouse Anti-Human
CD4, Clone MT310, conjugated with R-phycoerythrin (RPE),
and DAKO Monoclonal Mouse Anti-Human CD8, Clone DK25,
conjugated with fluorescein isothiocyanate isomer 1 (FITC). Gates
for PBMC (CD4+CD82) and SupT1 (CD4+CD8+) were set with
a separate control culture. After staining, the cells were analyzed in
a FACS Calibur system running with CellQuest Pro software (BD
Biosciences).
ELISA
The CA-p24 levels in the culture supernatants were measured
by ELISA as described by the manufacturer (Abbott Laboratories).
Statistical analysis
This study was repeated with ten different PBMC samples, and
similar results were obtained. The collected data were summarized
using means and standard deviations. Statistical significance (p)
was assessed using the unpaired Student’s t test.
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